Media stories about AVEO Pharmaceuticals (NASDAQ:AVEO) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AVEO Pharmaceuticals earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.8719982092447 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have impacted Accern Sentiment’s analysis:
- Technical Indicators in Focus – AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) – The Investor Guide (wallstreetnews24.com)
- AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) – Notable Indicators to Study Before Making Any Investment Decision – Nasdaq Journal (press release) (nasdaqjournal.com)
- Is Stock’s Performance Impressive? – AVEO Pharmaceuticals, Inc., (NASDAQ: AVEO) – Stock Watch (stocksnewstimes.com)
- Where to look at buying opportunities on AVEO Pharmaceuticals, Inc. (AVEO) – Wall Street Morning (wallstreetmorning.com)
- Analysts suggested mean rating score of 2.00 for AVEO Pharmaceuticals, Inc. (AVEO) – Wall Street Morning (wallstreetmorning.com)
Several brokerages recently commented on AVEO. Zacks Investment Research lowered shares of AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, December 6th. began coverage on shares of AVEO Pharmaceuticals in a report on Wednesday, November 15th. They issued a “buy” rating and a $5.00 price target for the company. B. Riley began coverage on shares of AVEO Pharmaceuticals in a report on Monday, November 13th. They issued a “buy” rating and a $5.00 price target for the company. Seaport Global Securities reissued a “buy” rating on shares of AVEO Pharmaceuticals in a report on Friday, October 6th. Finally, Piper Jaffray Companies lifted their target price on shares of AVEO Pharmaceuticals from $3.80 to $4.50 and gave the stock an “overweight” rating in a research note on Monday, August 28th. Two research analysts have rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. AVEO Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $4.05.
COPYRIGHT VIOLATION WARNING: This story was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.com-unik.info/2017/12/24/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-aveo-pharmaceuticals-aveo-stock-price.html.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.